Kate Luisi

Kate Luisi

Auto-generated profile, based on publicly available information

Kate Luisi

GSK, Rockville, MD 20850, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in Molecular Therapy
Verified
Journal Article
Open access
GMGiulietta Maruggi
Giulietta Maruggi
CMCorey P. Mallett
Corey P. Mallett
JWJason W. Westerbeck
Jason W. Westerbeck
TCTiffany Chen
Tiffany Chen
GLGiuseppe Lofano
Giuseppe Lofano
DYDong Yu
Dong Yu
RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the technology is being leveraged for rapid emergency response. In this report, we assessed immunogenicity and, for the first time, toxicity, biodistribution, and protective efficacy in preclinical models of a two-dose self-amplifying messenger RNA (SAM) vaccine, encoding a prefusion-stabilized spike antigen of SARS-CoV-2 Wuhan-Hu-1 strain and delivered by lipid nanoparticles (LNPs). In mice, one immunization with the SAM vaccine elicited a robust spike-specific antibody response, which was further boosted by a second immunization, and effectively neutralized the matched SARS-CoV-2 Wuhan strain as well as B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta) variants. High frequencies of spike-specific germinal center B, Th0/Th1 CD4, and CD8 T cell responses were observed in mice. Local tolerance, potential systemic toxicity, and biodistribution of the vaccine were characterized in rats. In hamsters, the vaccine candidate was well-tolerated, markedly reduced viral load in the upper and lower airways, and protected animals against disease in a dose-dependent manner, with no evidence of disease enhancement following SARS-CoV-2 challenge. Therefore, the SARS-CoV-2 SAM (LNP) vaccine candidate has a favorable safety profile, elicits robust protective immune responses against multiple SARS-CoV-2 variants, and has been advanced to phase 1 clinical evaluation (NCT04758962).

9 June 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
SCSumana Chandramouli
Sumana Chandramouli
EMEnrico Malito
Enrico Malito
TNTuongVi Nguyen
TuongVi Nguyen
KLKate Luisi
Kate Luisi
DDDanilo Donnarumma
Danilo Donnarumma
ACAndrea Carfi
Andrea Carfi
Structures of HCMV Pentamer in complex with neutralizing antibodies reveal immunogenic surfaces important for viral entry.

7 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
KLKate Luisi
Kate Luisi
KMKaitlyn Morabito
Kaitlyn Morabito
KBKatherine E. Burgomaster
Katherine E. Burgomaster
MSMayuri Sharma
Mayuri Sharma
WKWing-Pui Kong
Wing-Pui Kong
DYDong Yu
Dong Yu
A Zika self-amplifying mRNA vaccine delivered by a flexible bedside mixing formulation induces protective immunity in NHPs.